FDA 483_RESPONSE - Eli Lilly & Company - March 16, 2021

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Record Details

This 483 RESPONSE record concerns Eli Lilly & Company, with an inspection on March 16, 2021, issued by the Division of Pharmaceutical Quality Operations I, covering drugs.

Company: Eli Lilly & Company
Inspection Date: March 16, 2021
Product Type: Drugs
Office: Division of Pharmaceutical Quality Operations I
People: Art O. Czabaniuk (Program Division Director)
Ann Connery (Ms.)
Ainhoa Nieto
Kenneth O. Gee (Consumer Safety Officer)
Nicholas F. Lyons (Director of Compliance)

Open in Dashboard

ID · 48bca0f9-fb52-4f51-9e65-4d0fd6283a21

Violation Codes1

21 CFR 210

Full citation text and observation details available on the Dashboard.